Merrimack completes patient enrollment in Phase 3 MM-398 study

|About: Merrimack Pharmaceuticals (MACK)|By:, SA News Editor

Merrimack Pharmaceuticals (MACK) says it has reached its patient enrollment goal for a Phase 3 study of "MM-398, with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy." (PR)

See more on MM-398 here.